From its origins in groundbreaking research at The University of Queensland, to its use in more than 130 countries worldwide, the Gardasil® cervical cancer vaccine has led to an approximate 90 per cent decrease in the prevalence of human papillomavirus (HPV), the major cause of cervical cancer.